Heroin / 6-MAM
Diacetylmorphine (heroin) is a prodrug with an extremely short half-life (~6 min), rapidly deacetylated to 6-MAM (~38 min half-life), then to morphine. 6-MAM is the unique heroin biomarker; it is only detectable in urine for ~8 hours post-dose. Morphine persists for 2-3 days.
Projected serum levels — 10 mg, as needed (shown daily)
Maintenance schedule: 10 mg as needed (shown daily) (iv).
Modeled steady state after ~7 days: peak ≈ 0 mg, trough ≈ 0 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Opioid
- Route modeled
- IV
- Model confidence
- inferred
- Half-life
- 22 min
- Common dose
- 10 mg
- Reference dose range
- 5–20 mg (single dose)
- Suggested cadence
- as needed (shown daily)
Documented interactions
-
danger
1,4-BDO (1,4-Butanediol) + Heroin / 6-MAM
1,4-BDO converts to GHB; heroin is a potent opioid agonist. Combined respiratory depression is frequently fatal and offset timing makes overdose nearly impossible to titrate around.
-
danger
7-Hydroxymitragynine (7-OH) + Heroin / 6-MAM
7-Hydroxymitragynine (7-OH) and Heroin / 6-MAM both push the delta opioid, kappa opioid, and mu opioid in the same direction.
-
danger
Cocaine + Heroin / 6-MAM
Speedball: stimulant masks opioid sedation, leading to accidental overdose when cocaine wears off first. Extreme cardiac and respiratory risk.
-
danger
Codeine + Heroin / 6-MAM
Combining opioids causes additive respiratory depression.
-
danger
Ethanol (Alcohol) + Heroin / 6-MAM
Alcohol potentiates opioid respiratory depression. Heroin is already extremely high-risk for overdose.
-
danger
Fentanyl (IV/Nasal/Buccal — Non-Patch) + Heroin / 6-MAM
Fentanyl (IV/Nasal/Buccal — Non-Patch) and Heroin / 6-MAM both push the delta opioid, kappa opioid, and mu opioid in the same direction.
Serum checks 48 modeled interaction pairings for heroin / 6-mam across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Pharmacokinetics and Pharmacodynamics of High Doses of Pharmaceutically Prepared Heroin, by Intravenous or by Inhalation Route in Opioid-Dependent Patients
Characterized heroin and 6-MAM pharmacokinetics in opioid-dependent patients, showing heroin half-life of 2-6 minutes with rapid conversion to 6-MAM as the dominant compound in the first 30 minutes.
-
Pharmacokinetics and Pharmacokinetic Variability of Heroin and Its Metabolites: Review of the Literature
Comprehensive review of heroin pharmacokinetics across administration routes, detailing rapid esterase-mediated deacetylation to 6-MAM (half-life 6-25 min) and subsequent conversion to morphine.
-
6-Monoacetylmorphine (6-MAM), Not Morphine, Is Responsible for the Rapid Neural Effects Induced by Intravenous Heroin
Demonstrated that 6-MAM, not morphine, mediates the rapid neural effects of IV heroin due to its higher brain permeability and rapid formation from heroin metabolism.
3 published studies referenced in the app, each with a plain-language summary.